Internal Medicine: Open Access
Open Access

The Role of Medication in Parkinson’s Disease Management

Hannah Grace^{* *}Correspondence: Hannah Grace, Department of Medicine, University of Pennsylvania, Philadelphia, USA, Email:

Author info »

Description

Parkinson’s Disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the brain, leading to motor and non-motor symptoms. These symptoms include tremors, rigidity, bradykinesia (slowness of movement), postural instability, depression, sleep disturbances and cognitive decline. While there is currently no cure for Parkinson’s disease, medications play a important role in managing symptoms, improving quality of life, and slowing disease progression. This article explains the different classes of medications used in Parkinson’s disease management, their mechanisms of action, benefits, side effects and considerations in treatment planning [1].

The role of dopamine in Parkinson’s disease

Dopamine is a neurotransmitter that plays a critical role in coordinating movement, mood and cognition. In Parkinson’s disease, the loss of dopamine-producing neurons in the substantia nigra region of the brain disrupts normal dopamine levels, leading to impaired motor control and other symptoms. Medications used in PD primarily aim to restore or mimic dopamine’s effects in the brain to alleviate symptoms [2,3].

Key medications used in Parkinson’s disease management

Levodopa-Carbidopa: Levodopa is the most effective medication for managing motor symptoms in Parkinson’s Disease and is considered the gold standard of treatment. It is a precursor of dopamine, which means it is converted into dopamine in the brain, thereby replenishing depleted levels [4].

Mechanism of action: Levodopa crosses the blood-brain barrier and is converted to dopamine in the brain. Carbidopa is coadministered with levodopa to inhibit the enzyme dopa decarboxylase, which prevents the premature conversion of levodopa to dopamine outside the brain, enhancing its availability in the central nervous system.

Side effects: Common side effects include nausea, dizziness and orthostatic hypotension (a drop in blood pressure when standing up). Long-term use of levodopa can lead to motor complications, such as dyskinesia (involuntary movements) and motor fluctuations (on-off phenomena where medication effects wear off unpredictably) [5,6].

Dopamine agonists

Dopamine agonists, such as pramipexole, ropinirole and rotigotine mimic the action of dopamine in the brain by directly stimulating dopamine receptors.

Mechanism of action: Unlike levodopa, dopamine agonists do not require conversion to dopamine; instead, they directly stimulate dopamine receptors in the brain, producing effects similar to natural dopamine [7].

Side effects: Side effects may include drowsiness, hallucinations, impulsive behaviors (e.g., gambling or hypersexuality) and peripheral edema. Older patients are more susceptible to these neuropsychiatric side effects, which can limit their use.

Monoamine Oxidase-B (MAO-B) inhibitors

MAO-B inhibitors, such as selegiline, rasagiline and safinamide work by blocking the enzyme monoamine oxidase-B, which breaks down dopamine in the brain, thereby increasing its availability.

Mechanism of action: MAO-B inhibitors inhibit the breakdown of dopamine in the brain, enhancing and prolonging the effects of both endogenous dopamine and dopamine from medications like levodopa.

Side effects: Potential side effects include insomnia, headaches and gastrointestinal disturbances. MAO-B inhibitors are generally well-tolerated, but caution is needed when used with other serotonergic drugs due to the risk of serotonin syndrome.

Catechol-O-Methyltransferase (COMT) inhibitors

COMT inhibitors, such as entacapone and opicapone, are used in combination with levodopa to prolong its effects by preventing its breakdown outside the brain.

Mechanism of action: COMT inhibitors block the COMT enzyme, which breaks down levodopa in the periphery, thus enhancing and extending levodopa’s effectiveness in the brain.

Side effects: Side effects can include diarrhea, urine discoloration and dyskinesias. These drugs are usually well tolerated, but close monitoring is essential [8,9].

Anticholinergics

Anticholinergics, such as benztropine and trihexyphenidyl, were among the first drugs used to treat Parkinson’s Disease. They primarily help manage tremors.

Mechanism of action: Anticholinergics work by blocking the action of acetylcholine, a neurotransmitter that can be overly active when dopamine levels are low, leading to tremors and muscle stiffness.

Side effects: Side effects can include dry mouth, blurred vision, constipation, urinary retention and cognitive impairment, making these drugs less suitable for older adults.

Amantadine

Amantadine is an antiviral medication with dopaminergic and anti-glutamatergic properties that help reduce dyskinesias and mild motor symptoms.

Mechanism of action: Amantadine increases dopamine release and blocks glutamate receptors, which may help modulate motor activity.

Side effects: Side effects can include confusion, hallucinations, and leg edema. It is often used with caution in elderly patients due to its cognitive effects.

Considerations in medication management

The management of Parkinson’s disease with medication is highly individualized, taking into account the patient’s age, stage of disease, symptom severity, comorbidities and response to treatment.

Personalized treatment plans: As PD progresses, patients may require adjustments in their medication regimen, including changes in dosages, timing and the addition of new drugs to manage motor fluctuations and non-motor symptoms.

Monitoring and adjusting therapy: Regular follow-ups with healthcare providers are essential to assess the effectiveness of medications and make necessary adjustments. Close monitoring helps manage side effects and optimize symptom control [10].

Conclusion

Medications play a central role in managing Parkinson’s disease by restoring dopamine function, alleviating motor symptoms and improving patients overall quality of life. The choice of medication and treatment approach must be tailored to the individual needs of each patient, with ongoing adjustments to address the evolving nature of the disease. While pharmacological treatment remains the cornerstone of PD management, a holistic approach that includes lifestyle modifications, non-pharmacological therapies and patient education is essential for optimal care. As research continues to advance, new medications and treatment strategies hold promise for further improving the lives of those living with Parkinson’s disease.

References

1. Dong C, Chen Y, Huan Z, Li Z, Gao G, Zhou B. An “optical flow” method based on pressure sensors data for quantification of Parkinson's disease characteristics. Biomed Signal Process Control. 2023; 81:104377.

   [Crossref] [Google Scholar]

2. Balakrishnan A, Medikonda J, Namboothiri PK, Natarajan M. Mahalanobis Metric-based Oversampling Technique for Parkinson’s Disease Severity Assessment using Spatiotemporal Gait Parameters. Biomed Signal Process Control. 2023; 86:105057.

   [Crossref] [Google Scholar]

3. Prashanth R, Roy SD, Mandal PK, Ghosh S. High-accuracy detection of early Parkinson's disease through multimodal features and machine learning. Int J Med Inform. 2016; 90:13-21.

   [Crossref] [Google Scholar] [Pubmed]

4. Almeida JS, Rebouças Filho PP, Carneiro T, Wei W, Damaševičius R, Maskeliūnas R, et al. Detecting Parkinson’s disease with sustained phonation and speech signals using machine learning techniques. Pattern Recognit. Lett. 2019; 125:55-62.

   [Crossref] [Google Scholar]

5. Amato F, Saggio G, Cesarini V, Olmo G, Costantini G. Machine learning-and statistical-based voice analysis of Parkinson’s disease patients: A survey. Expert Systems with Applications. 2023; 219:119651.

   [Crossref] [Google Scholar]

6. Godino-Llorente JI, Shattuck-Hufnagel S, Choi JY, Moro-Velázquez L, Gómez-García JA. Towards the identification of Idiopathic Parkinson’s Disease from the speech. New articulatory kinetic biomarkers. PLoS One. 2017; 12(12):e0189583.

   [Crossref] [Google Scholar] [Pubmed]

7. Tur EK, Ari BC. The impact of COVID-19 pandemic on clinical and neuropsychological importance of Parkinson’s disease patients. J Neurol Sci. 2023; 455.

   [Crossref] [Google Scholar]

8. Liu Q, Jiang B, Zou M, Wan HJ, Yu ZW, Wang J, et al. A genetic analysis of Chinese patients with early-onset Parkinson’s disease. Neurosci Lett. 2022; 790:136880.

   [Crossref] [Google Scholar] [Pubmed]

9. Salimjonov J, Matmurodov R, Muminov B. Clinical course of Parkinson’s disease in patients with COVID-19. J Neurol Sci. 2023; 455.

   [Crossref] [Google Scholar]

10. Arora S, Baghai-Ravary L, Tsanas A. Developing a large scale population screening tool for the assessment of Parkinson's disease using telephone-quality voice. J Acoust Soc Am. 2019; 145(5):2871-2884.

    [Crossref] [Google Scholar] [Pubmed]